Global mTOR (Mammalian target of rapamycin) Inhibitors Market 2019-2023
About this market
The strong prevalence of oncology indications is one of the key factors expected to trigger market growth during the forecast period. Vendors are conducting studies on target specific drugs to meet the gap between the demand and supply of these therapies. Factors including the increasing geriatric population and changes in lifestyle have also contributed to the oncology indications, in turn, contributing to the mTOR Inhibitors market growth during the forecast period. Technavio’s analysts have predicted that the mTOR inhibitors market will register a CAGR of over 3% by 2023.
Introduction of novel drug delivery systems and combination therapies
Chemotherapeutic drugs are mostly administered through conventional methods to treat different tumors. And, it is observed that the API does not reach the targeted site in appropriate quantities, thus lowering the performance of the drugs.
Adverse effects of available therapeutics
Despite being highly efficacious, mTOR inhibitors used for treating various oncology indications are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
For the detailed list of factors that will drive and challenge the growth of the mTOR inhibitors market during 2019-2023, view our report.
The market appears to be concentrated and with the presence of few companies including Biocon Ltd. and Intas Pharmaceuticals Ltd., the competitive environment is quite intense. Various international and national organizations are focusing on conducting programs to increase awareness about cancer and help early diagnosis of the disease. Novartis AG, Pfizer Inc., and Zydus Cadila. are some of the major companies covered in this report.
Intas Pharmaceuticals Ltd.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook